U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies by Smith, MA, Choudhary, GS, Pellagatti, A, Choi, K, Bolanos, LC, Bhagat, TD, Gordon-Mitchell, S, Von Ahrens, D, Pradhan, K, Steeples, V, Kim, S, Steidl, U, Walter, M, Fraser, IDC, Kulkarni, A, Salomonis, N, Komurov, K, Boultwood, J, Verma, A, Starczynowski, DT

Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations by Choudhary, GS, Pellagatti, A, Agianian, B, Smith, MA, Bhagat, TD, Gordon-Mitchell, S, Sahu, S, Pandey, S, Shah, N, Aluri, S, Aggarwal, R, Aminov, S, Schwartz, L, Steeples, V, Booher, RN, Ramachandra, M, Samson, M, Carbajal, M, Pradhan, K, Bowman, TV, Pillai, MM, Will, B, Wickrema, A, Shastri, A, Bradley, RK, Martell, RE, Steidl, UG, Gavathiotis, E, Boultwood, J, Starczynowski, DT, Verma, A

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine by Rahmani, NE, Ramachandra, N, Sahu, S, Gitego, N, Lopez, A, Pradhan, K, Bhagat, TD, Gordon-Mitchell, S, Pena, BR, Kazemi, M, Rao, K, Giricz, O, Maqbool, SB, Olea, R, Zhao, Y, Zhang, J, Dolatshad, H, Tittrea, V, Tatwavedi, D, Singh, S, Lee, J, Sun, T, Steidl, U, Shastri, A, Inoue, D, Abdel-Wahab, O, Pellagatti, A, Gavathiotis, E, Boultwood, J, Verma, A